Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab (Q38119307)

29 August 2017

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab (English)

1 reference

29 August 2017

metastatic breast cancer

1 reference

W J Gradishar

1

1 reference

29 August 2017

4 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

24

1 reference

29 August 2017

10

1 reference

29 August 2017

2492-2500

1 reference

European cancer mortality predictions for the year 2013.

29 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Primary trastuzumab resistance: new tricks for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT217

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT217

1 reference

29 August 2017

1 reference

PubMed ID

23827380